Breast cancer patients receiving adjuvant Docetaxel and Cyclophosphamide chemotherapy: efficacy of scalp cooling in preventing chemotherapy-induced alopecia
Chemotherapy-induced alopecia ( CIA ) is a distressing adverse effect of many chemotherapy agents. The TC ( Docetaxel [ Taxotere ] and Cyclophosphamide ) chemotherapy regimen is typically associated with complete alopecia.
Scalp cooling with cold caps has been reported to minimize or prevent chemotherapy-induced alopecia.
Researchers have conducted a prospective study to assess efficacy of scalp cooling in preventing chemotherapy-induced alopecia among women receiving adjuvant TC chemotherapy for breast cancer.
Women at the Weill Cornell Breast Center who independently elected to use scalp cooling with cold caps during adjuvant TC chemotherapy were asked to participate.
Degree of hair loss was assessed by a single practitioner using Dean's alopecia scale ( grade 1/excellent [ less than 25% hair loss ], grade 2/good [ 25-50% hair loss ], grade 3/moderate [ 50-75% hair loss ], grade 4/poor [ more than 75% hair loss ] ), by digital photographs, and by patient self-report of hair thinning or the need to wear a wig/head covering, or both.
Assessments were made before each chemotherapy treatment and at follow-up visits between 3 weeks and 3 months after completion of chemotherapy.
Of 20 evaluable patients, 10% reported a need to wear a wig/head covering at the follow-up visit.
Dean's alopecia score was excellent for 65% of patients, good for 25% of patients, and moderate or poor for 10% of patients.
The majority of patients reported hair thinning after every chemotherapy cycle.
No patient discontinued therapy because of an intolerance to cold caps.
In conclusion, scalp cooling with cold caps appears to be effective in preventing chemotherapy-induced alopecia among the majority of women undergoing treatment with TC chemotherapy. ( Xagena )
Cigler T et al, Clin Breast Cancer 2015; Epub ahead of print